David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold shares of the company amounting to $101,103. The transaction, which occurred on January 22, 2025, ...

David O. Watson, the General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold a portion of his holdings in the company. According to a regulatory filing, Watson sold 695 shares of ...

The company had planned to launch the generic version of Actos on August 17th, after a 2010 settlement with the Japanese drugmaker, Takeda Pharmaceuticals. Watson believes that the FDA improperly ...

KBC Group NV grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,862.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange ...

Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 Morgan Stanley Raises PT On Watson Pharmaceuticals To $78 Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 ...

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg. Sildenafil is the ...